Delhi HC seeks Dr Reddy's reply in Novo patent dispute

Mumbai A division bench of the Delhi High Court on Wednesday ordered Dr Reddy's Labs to file its reply to the injunction petition moved by Danish drug maker Novo Nordisk for its blockbuster weight-loss drug semaglutide, which is sold under the brand name Wegovy.

An expert in intellectual property laws told ET that the order may require Dr Reddy's Labs to explain the grounds for exports of weight-loss drug semaglutide.

The court's directive comes on the back of a plea by Novo Nordisk, which alleged patent infringement. The patent for the weight-loss drug is slated to end in March next year.